FibroGen, Inc. (FGEN) |
|
18.66 -0.07 (-0.37%)
|
03-31 16:00 |
|
Open: |
18.83 |
Pre. Close: |
18.73 |
|
High:
|
19.07 |
Low:
|
18.455 |
|
Volume:
|
869,149 |
Market Cap:
|
1,757(M) |
|
|
|
Technical analysis |
as of: 2023-03-31 4:18:40 PM |
|
Overall:
|
 |
| Stoxline posted a BUY today, same as yesterday. Upward movement continues. |
| Target: |
Six months: 25.03 One year: 27.48 |
| Support: |
Support1: 18.04 Support2: 15 |
| Resistance: |
Resistance1: 21.43 Resistance2: 23.53 |
| Pivot: |
19.29  |
| Moving Average: |
MA(5): 18.87  MA(20): 19.69
MA(100): 18.82 MA(250): 14.86 |
| MACD: |
MACD(12,26): -0.9 Signal(9): -0.8 |
| Stochastic oscillator: |
%K(14,3): 30.7 %D(3): 29.6 |
| RSI: |
RSI(14): 35.2 |
| 52-week: |
High: 25.69 Low: 7.8 |
| Average Vol(K): |
3-Month: 957 (K) 10-Days: 704 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ FGEN ] has closed above bottom band by 26.5%. Bollinger Bands are 36.1% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
19.55 - 19.65 |
19.65 - 19.72 |
|
Low:
|
18.34 - 18.44 |
18.44 - 18.52 |
|
Close:
|
18.57 - 18.74 |
18.74 - 18.87 |
|
Company Description |
|
FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States, Europe, China, and Japan; and in Phase II/III development in China for anemia associated with myelodysplastic syndromes. It is also developing Pamrevlumab, a human monoclonal antibody that inhibits the activity of connective tissue growth factor that is in Phase III clinical development for the treatment of idiopathic pulmonary fibrosis, pancreatic cancer, liver fibrosis, and diabetic kidney disease, as well as Phase III trial for the treatment of Duchenne muscular dystrophy. The company has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. FibroGen, Inc. was incorporated in 1993 and is headquartered in San Francisco, California. |
Headline News |
Fri, 31 Mar 2023
FibroGen, Inc. (NASDAQ:FGEN) Short Interest Up 20.1% in March - MarketBeat
Wed, 29 Mar 2023
FibroGen Faces An Uphill Battle In Idiopathic Pulmonary Fibrosis ... - Seeking Alpha
Wed, 29 Mar 2023
FibroGen: Despite Some Progress, Roxadustat's Data Disaster Still ... - Seeking Alpha
Thu, 23 Mar 2023
Newbridge Financial Services Group Inc. Sells 6750 Shares of ... - MarketBeat
Tue, 21 Mar 2023
Why did Sarepta Therapeutics Stock Plummet? - Nasdaq
Mon, 13 Mar 2023
Enrique Conterno Is The CEO & Director of FibroGen, Inc. (NASDAQ:FGEN) And They Just Sold 29% Of Their Shares - Simply Wall St
|
Financial Analysis |
| Price to Book Value: |
Underperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Underperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Underperform |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Outperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Underperform |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
94 (M) |
| Shares Float |
83 (M) |
|
% Held by Insiders
|
8 (%) |
|
% Held by Institutions
|
80.5 (%) |
|
Shares Short
|
4,020 (K) |
|
Shares Short P.Month
|
4,420 (K) |
Stock Financials |
|
EPS
|
-3.15 |
|
EPS Est Next Qtl
|
-0.47 |
|
EPS Est This Year
|
-1.81 |
|
EPS Est Next Year
|
-0.95 |
|
Book Value (p.s.)
|
-0.24 |
|
Profit Margin (%)
|
-208.7 |
|
Operating Margin (%)
|
-213.9 |
|
Return on Assets (ttm)
|
-27.2 |
|
Return on Equity (ttm)
|
-258.1 |
|
Qtrly Rev. Growth
|
107.6 |
|
Gross Profit (p.s.)
|
1.27 |
|
Sales Per Share
|
1.49 |
|
EBITDA (p.s.)
|
-3.09 |
|
Qtrly Earnings Growth
|
0 |
|
Operating Cash Flow
|
-146 (M) |
|
Levered Free Cash Flow
|
-170 (M) |
Stock Valuations |
|
PE Ratio
|
-5.95 |
|
PEG Ratio
|
0 |
|
Price to Book value
|
-81.14 |
|
Price to Sales
|
12.48 |
|
Price to Cash Flow
|
-12.05 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
0 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
